JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT04252586
- Locations
- 🇪🇸
Clinical Trial Site #1, Madrid, Spain
🇬🇧Clinical Trial Site, London, United Kingdom
🇪🇸Clinical Trial Site #2, Madrid, Spain
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT04224272
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸UCLA Hematology/Oncology Parkside, Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT04203498
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇵🇱Neurologiczny NZOZ Centrum Leczenia SM Ośrodek Badań Klinicznych im. dr n. med. Hanki Hertmanowskiej Witosław Cieślak, Plewiska, Poland
🇺🇸Neurostudies - Port Charlotte, Port Charlotte, Florida, United States
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
- Conditions
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04145531
- Locations
- 🇺🇸
Scottish Rite Hospital, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT04133480
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT04075747
- Locations
- 🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT04038437
- Locations
- 🇺🇸
Blood & Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Dana Farber/ Brigham & Women's Cancer Center, Boston, Massachusetts, United States
A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT03954106
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 74
- Registration Number
- NCT03929666
- Locations
- 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT03848832
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom